DERM vs. PGEN, TNGX, TRVI, CMRX, SNDL, BTMD, VYGR, LFVN, ITOS, and IMMP
Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Precigen (PGEN), Tango Therapeutics (TNGX), Trevi Therapeutics (TRVI), Chimerix (CMRX), SNDL (SNDL), biote (BTMD), Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry.
Journey Medical vs.
Journey Medical (NASDAQ:DERM) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
7.3% of Journey Medical shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 13.2% of Journey Medical shares are held by insiders. Comparatively, 44.9% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Journey Medical has higher revenue and earnings than Precigen. Journey Medical is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Precigen had 5 more articles in the media than Journey Medical. MarketBeat recorded 7 mentions for Precigen and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.95 beat Precigen's score of 0.48 indicating that Journey Medical is being referred to more favorably in the media.
Precigen received 431 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 67.39% of users gave Precigen an outperform vote.
Journey Medical has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Precigen has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Journey Medical currently has a consensus price target of $9.38, suggesting a potential upside of 148.02%. Precigen has a consensus price target of $7.00, suggesting a potential upside of 436.40%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Journey Medical.
Journey Medical has a net margin of -31.74% compared to Precigen's net margin of -3,521.68%. Precigen's return on equity of -123.06% beat Journey Medical's return on equity.
Summary
Precigen beats Journey Medical on 10 of the 18 factors compared between the two stocks.
Get Journey Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Journey Medical Competitors List
Related Companies and Tools
This page (NASDAQ:DERM) was last updated on 1/23/2025 by MarketBeat.com Staff
